Gilead's Trodelvy triplet underwhelms, but bolsters company's phase 3 lung cancer design

Gilead Sciences has been looking for a win for Trodelvy after two surprise trial failures earlier this year. But it looks like that win won’t come from a triplet regimen that combines the antibody-drug conjugate with Merck’s Keytruda and chemotherapy in newly diagnosed non-small cell lung cancer (NSCLC)